This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Decaudin, D. Articles by Solal-Céligny, P. Search for Related Content PubMed PubMed Citation Articles by Decaudin, D. Articles by Solal-Céligny, P. Social Bookmarking                            What's this?

Low-Grade Stage III-IV Follicular Lymphoma: Multivariate Analysis of Prognostic Factors in 484 Patients—A Study of the Groupe d'Etude des Lymphomes de l'Adulte

From the Groupe d'Etude des Lymphomes de l'Adulte, Créteil, Paris, Nantes, Rouen, Caen, Lyon, and Le Mans, France, and Yvoir, Belgium.

Address reprint requests to Didier Decaudin, MD, PhD, Department of Hematology, Institut Curie, 26 rue d'Ulm, 75.248 Paris cedex 05, France; email didier.decaudin{at}curie.fr

PURPOSE: To identify the prognostic factors that influence overall survival (OS) in patients with stage III-IV follicular lymphomas and evaluate the clinical usefulness and the prognostic value of the International Prognostic Index (IPI).

PATIENTS AND METHODS: Four hundred eighty-four patients with Ann Arbor stage III-IV follicular lymphomas treated in two phase III trials from 1986 to 1995 were screened for this study. All histologic slides were reviewed by two hematopathologists. The influence of the initial parameters on survival was defined by univariate (log-rank test) and multivariate (Cox model) analyses.

RESULTS: The poor prognostic factors for OS (age > 60 years, "B" symptom(s), two extranodal sites, stage IV disease, tumor bulk > 7 cm, at least three nodal sites > 3 cm, liver involvement, serous effusion-compression or orbital/epidural involvement, and erythrocyte sedimentation rate > 30 mm/h) that were significant in univariate analysis were subjected to multivariate analysis. Three factors remained significant: B symptom(s) (risk ratio = 1.80), age greater than 60 years (risk ratio = 1.60), and at least three nodal sites greater than 3 cm (risk ratio = 1.71). When the IPI was applied to these patients, the score was 1, 2, 3, and 4-5 in 49%, 39%, 11%, and 2%, respectively, and it was significant for progression-free survival (P = .002) and OS (P = .0001).

CONCLUSION: Three prognostic factors for poor OS were identified: B symptoms, age greater than 60 years, and at least three nodal sites greater than 3 cm. The IPI was prognostic for OS, but in this population, a very low number of patients belonged to the high-risk groups.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. A. M. van de Schans, E. W. Steyerberg, M. R. Nijziel, G.-J. Creemers, M. L. Janssen-Heijnen, and D. J. van Spronsen Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting Ann. Onc., October 1, 2009; 20(10): 1697 - 1702. [Abstract] [Full Text] [PDF]

				F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Oncologist, October 1, 2009; 14(suppl_2): 17 - 29. [Abstract] [Full Text] [PDF]

				M. Federico, M. Bellei, L. Marcheselli, S. Luminari, A. Lopez-Guillermo, U. Vitolo, B. Pro, S. Pileri, A. Pulsoni, P. Soubeyran, et al. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project J. Clin. Oncol., September 20, 2009; 27(27): 4555 - 4562. [Abstract] [Full Text] [PDF]

				G. Perea, A. Altes, S. Montoto, A. Lopez-Guillermo, E. Domingo-Domenech, A. Fernandez-Sevilla, J. M. Ribera, J. Grau, C. Pedro, J. Angel Hernandez, et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems Ann. Onc., September 1, 2005; 16(9): 1508 - 1513. [Abstract] [Full Text] [PDF]

				C. Gulmann, V. Espina, E. Petricoin III, D. L. Longo, M. Santi, T. Knutsen, M. Raffeld, E. S. Jaffe, L. A. Liotta, and A. L. Feldman Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma Clin. Cancer Res., August 15, 2005; 11(16): 5847 - 5855. [Abstract] [Full Text] [PDF]

				A. Koster, J. H.J.M. van Krieken, M. A. MacKenzie, M. Schraders, G. F. Borm, J. A.W.M. van der Laak, W. Leenders, K. Hebeda, and J. M.M. Raemaekers Increased Vascularization Predicts Favorable Outcome in Follicular Lymphoma Clin. Cancer Res., January 1, 2005; 11(1): 154 - 161. [Abstract] [Full Text] [PDF]

				A. M. Glas, M. J. Kersten, L. J. M. J. Delahaye, A. T. Witteveen, R. E. Kibbelaar, A. Velds, L. F. A. Wessels, P. Joosten, R. M. Kerkhoven, R. Bernards, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment Blood, January 1, 2005; 105(1): 301 - 307. [Abstract] [Full Text] [PDF]

				S. S. Dave, G. Wright, B. Tan, A. Rosenwald, R. D. Gascoyne, W. C. Chan, R. I. Fisher, R. M. Braziel, L. M. Rimsza, T. M. Grogan, et al. Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells N. Engl. J. Med., November 18, 2004; 351(21): 2159 - 2169. [Abstract] [Full Text] [PDF]

				J. P. Leonard The "FLIPI" is no "FLOPI" Blood, September 1, 2004; 104(5): 1233 - 1234. [Full Text] [PDF]

				P. Solal-Celigny, P. Roy, P. Colombat, J. White, J. O. Armitage, R. Arranz-Saez, W. Y. Au, M. Bellei, P. Brice, D. Caballero, et al. Follicular Lymphoma International Prognostic Index Blood, September 1, 2004; 104(5): 1258 - 1265. [Abstract] [Full Text] [PDF]

				H. C. Schouten, W. Qian, S. Kvaloy, A. Porcellini, H. Hagberg, H. E. Johnsen, J. K. Doorduijn, M. R. Sydes, and G. Kvalheim High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin's Lymphoma: Results From the Randomized European CUP Trial J. Clin. Oncol., November 1, 2003; 21(21): 3918 - 3927. [Abstract] [Full Text] [PDF]

				W. S. Velasquez, D. Lew, T. M. Grogan, C. H. Spiridonidis, S. P. Balcerzak, S. R. Dakhil, T. P. Miller, K. S. Lanier, R. A. Chapman, and R. I. Fisher Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501 J. Clin. Oncol., May 15, 2003; 21(10): 1996 - 2003. [Abstract] [Full Text] [PDF]

				D. Decaudin, G. Des Guetz, C. Mathiot, J. Dumont, P. Hubert, A. Vincent-Salomon, and P. Pouillart Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy Ann. Onc., January 1, 2003; 14(1): 171 - 172. [Full Text] [PDF]

				E. Maartense, S. le Cessie, H. C. Kluin-Nelemans, P. M. Kluin, S. Snijder, P. W. Wijermans, and E. M. Noordijk Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry Ann. Onc., August 1, 2002; 13(8): 1275 - 1284. [Abstract] [Full Text] [PDF]